Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST

LDT for Thyroid Cancer Now Reimbursed for Over 110 Million Patients

by

Company press release: Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis.

The Afirma® test offered by Veracyte measures 142 genes by RNA expression array (manufactured by Affymetrix) to provide the likelihood that thyroid nodules of indeterminate nature (as classified by a cytopathologist) are cancerous and thus deserving of surgical intervention.